Literature DB >> 32727838

Vaccination in B-cell-depleted patients with multiple sclerosis.

Joep Killestein1, Renaud Du Pasquier2, Bernhard Hemmer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32727838     DOI： 10.1212/WNL.0000000000010378

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  3 in total

1.  B cell therapy and the use of RNA-based COVID-19 vaccines.

Authors:  Anastasia Vishnevetsky; Chris Hawkes; Jeannette Lechner-Scott; Gavin Giovannoni; Michael Levy; Daniela Pohl
Journal:  Mult Scler Relat Disord       Date:  2021-03-08       Impact factor: 4.339

2.  COVID-19 in ocrelizumab-treated people with multiple sclerosis.

Authors:  Richard Hughes; Louise Whitley; Kocho Fitovski; Hans-Martin Schneble; Erwan Muros; Annette Sauter; Licinio Craveiro; Paul Dillon; Ulrike Bonati; Nikki Jessop; Rosetta Pedotti; Harold Koendgen
Journal:  Mult Scler Relat Disord       Date:  2020-12-30       Impact factor: 4.339

3.  Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.

Authors:  Hamza Mahmood Bajwa; Frederik Novak; Anna Christine Nilsson; Christian Nielsen; Dorte K Holm; Kamilla Østergaard; Agnes Hauschultz Witt; Keld-Erik Byg; Isik S Johansen; Kristen Mittl; William Rowles; Scott S Zamvil; Riley Bove; Joseph J Sabatino; Tobias Sejbaek
Journal:  Mult Scler Relat Disord       Date:  2022-03-06       Impact factor: 4.808
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.